APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease IVD

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurodegenerative Disease IVD Market Analysis and Forecast 2026-2032

16 April 2026225 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease IVD Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease IVD Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease IVD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease IVD Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease IVD Market Analysis and Forecast 2026-2032225 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease IVD market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neurodegenerative Disease IVD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neurodegenerative Disease IVD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neurodegenerative Disease IVD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neurodegenerative Disease IVD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neurodegenerative Disease IVD include ADx Neurosciences, Analytik Jena, Beckman Coulter, Creative Biolabs, Fujirebio, Genemedi, Medix Biochemica, Revvity and Roche Diagnostics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neurodegenerative Disease IVD, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurodegenerative Disease IVD, also provides the revenue of main regions and countries. Of the upcoming market potential for Neurodegenerative Disease IVD, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurodegenerative Disease IVD revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurodegenerative Disease IVD market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neurodegenerative Disease IVD revenue, projected growth trends, production technology, application and end-user industry.

Neurodegenerative Disease IVD Segment by Company

ADx Neurosciences

Analytik Jena

Beckman Coulter

Creative Biolabs

Fujirebio

Genemedi

Medix Biochemica

Revvity

Roche Diagnostics

Neurodegenerative Disease IVD Segment by Type

Protein Biomarker Detection

Nucleic Acid Biomarker Detection

Others

Neurodegenerative Disease IVD Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease IVD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease IVD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease IVD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease IVD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neurodegenerative Disease IVD in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neurodegenerative Disease IVD company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease IVD revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease IVD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Protein Biomarker Detection Major Player Table 3. Nucleic Acid Biomarker Detection Major Player Table 4. Others Major Player Table 5. Global Neurodegenerative Disease IVD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Alzheimer's Disease Major Player Table 7. Parkinson's Disease Major Player Table 8. Huntington's Disease Major Player Table 9. Amyotrophic Lateral Sclerosis (ALS) Major Player Table 10. Multiple System Atrophy (MSA) Major Player Table 11. Progressive Supranuclear Palsy (PSP) Major Player Table 12. Others Major Player Table 13. Neurodegenerative Disease IVD Industry Trends Table 14. Neurodegenerative Disease IVD Industry Drivers Table 15. Neurodegenerative Disease IVD Industry Opportunities and Challenges Table 16. Neurodegenerative Disease IVD Industry Restraints Table 17. Global Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Neurodegenerative Disease IVD Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Neurodegenerative Disease IVD Market Share by Region (2021-2026) Table 20. Global Neurodegenerative Disease IVD Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Neurodegenerative Disease IVD Market Share by Region (2027-2032) Table 22. Global Neurodegenerative Disease IVD Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Neurodegenerative Disease IVD Revenue Market Share by Players (2021-2026) Table 24. Global Neurodegenerative Disease IVD Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Neurodegenerative Disease IVD Key Players Headquarters & Area Served Table 26. Global Neurodegenerative Disease IVD Players, Product Type & Application Table 27. Global Neurodegenerative Disease IVD Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Neurodegenerative Disease IVD by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Neurodegenerative Disease IVD Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neurodegenerative Disease IVD Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Neurodegenerative Disease IVD Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Neurodegenerative Disease IVD Revenue Market Share by Type (2021-2026) Table 34. Global Neurodegenerative Disease IVD Revenue Market Share by Type (2027-2032) Table 35. Global Neurodegenerative Disease IVD Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neurodegenerative Disease IVD Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Neurodegenerative Disease IVD Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2021-2026) Table 39. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2027-2032) Table 40. ADx Neurosciences Company Information Table 41. ADx Neurosciences Business Overview Table 42. ADx Neurosciences Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio Table 44. ADx Neurosciences Recent Development Table 45. Analytik Jena Company Information Table 46. Analytik Jena Business Overview Table 47. Analytik Jena Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Analytik Jena Neurodegenerative Disease IVD Product Portfolio Table 49. Analytik Jena Recent Development Table 50. Beckman Coulter Company Information Table 51. Beckman Coulter Business Overview Table 52. Beckman Coulter Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Beckman Coulter Neurodegenerative Disease IVD Product Portfolio Table 54. Beckman Coulter Recent Development Table 55. Creative Biolabs Company Information Table 56. Creative Biolabs Business Overview Table 57. Creative Biolabs Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Creative Biolabs Neurodegenerative Disease IVD Product Portfolio Table 59. Creative Biolabs Recent Development Table 60. Fujirebio Company Information Table 61. Fujirebio Business Overview Table 62. Fujirebio Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Fujirebio Neurodegenerative Disease IVD Product Portfolio Table 64. Fujirebio Recent Development Table 65. Genemedi Company Information Table 66. Genemedi Business Overview Table 67. Genemedi Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Genemedi Neurodegenerative Disease IVD Product Portfolio Table 69. Genemedi Recent Development Table 70. Medix Biochemica Company Information Table 71. Medix Biochemica Business Overview Table 72. Medix Biochemica Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Medix Biochemica Neurodegenerative Disease IVD Product Portfolio Table 74. Medix Biochemica Recent Development Table 75. Revvity Company Information Table 76. Revvity Business Overview Table 77. Revvity Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Revvity Neurodegenerative Disease IVD Product Portfolio Table 79. Revvity Recent Development Table 80. Roche Diagnostics Company Information Table 81. Roche Diagnostics Business Overview Table 82. Roche Diagnostics Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio Table 84. Roche Diagnostics Recent Development Table 85. North America Neurodegenerative Disease IVD Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Neurodegenerative Disease IVD Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Neurodegenerative Disease IVD Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Neurodegenerative Disease IVD Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Neurodegenerative Disease IVD Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Neurodegenerative Disease IVD Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Neurodegenerative Disease IVD Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Neurodegenerative Disease IVD Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Neurodegenerative Disease IVD Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Neurodegenerative Disease IVD Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Neurodegenerative Disease IVD Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Neurodegenerative Disease IVD Revenue by Country (US$ Million) & (2027-2032) Table 99. China Neurodegenerative Disease IVD Revenue by Type (2021-2026) & (US$ Million) Table 100. China Neurodegenerative Disease IVD Revenue by Type (2027-2032) & (US$ Million) Table 101. China Neurodegenerative Disease IVD Revenue by Application (2021-2026) & (US$ Million) Table 102. China Neurodegenerative Disease IVD Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Neurodegenerative Disease IVD Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Neurodegenerative Disease IVD Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Neurodegenerative Disease IVD Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Neurodegenerative Disease IVD Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Neurodegenerative Disease IVD Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Neurodegenerative Disease IVD Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Neurodegenerative Disease IVD Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Neurodegenerative Disease IVD Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Neurodegenerative Disease IVD Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Neurodegenerative Disease IVD Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Neurodegenerative Disease IVD Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Neurodegenerative Disease IVD Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Neurodegenerative Disease IVD Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Neurodegenerative Disease IVD Image Figure 2. Global Neurodegenerative Disease IVD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Disease IVD Market Size Share 2021 VS 2025 VS 2032 Figure 4. Protein Biomarker Detection Image Figure 5. Nucleic Acid Biomarker Detection Image Figure 6. Others Image Figure 7. Global Neurodegenerative Disease IVD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neurodegenerative Disease IVD Market Size Share 2021 VS 2025 VS 2032 Figure 9. Alzheimer's Disease Image Figure 10. Parkinson's Disease Image Figure 11. Huntington's Disease Image Figure 12. Amyotrophic Lateral Sclerosis (ALS) Image Figure 13. Multiple System Atrophy (MSA) Image Figure 14. Progressive Supranuclear Palsy (PSP) Image Figure 15. Others Image Figure 16. Global Neurodegenerative Disease IVD Market Size (US$ Million) & (2021-2032) Figure 17. Global Neurodegenerative Disease IVD Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Neurodegenerative Disease IVD Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Neurodegenerative Disease IVD Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Neurodegenerative Disease IVD Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neurodegenerative Disease IVD Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Neurodegenerative Disease IVD Revenue Market Share by Type (2021-2032) Figure 24. Global Neurodegenerative Disease IVD Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2021-2032) Figure 27. North America Neurodegenerative Disease IVD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Neurodegenerative Disease IVD Revenue Share by Type (2021-2032) Figure 29. North America Neurodegenerative Disease IVD Revenue Share by Application (2021-2032) Figure 30. North America Neurodegenerative Disease IVD Revenue Share by Country (2021-2032) Figure 31. United States Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Neurodegenerative Disease IVD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Neurodegenerative Disease IVD Revenue Share by Type (2021-2032) Figure 36. Europe Neurodegenerative Disease IVD Revenue Share by Application (2021-2032) Figure 37. Europe Neurodegenerative Disease IVD Revenue Share by Country (2021-2032) Figure 38. Germany Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Neurodegenerative Disease IVD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Neurodegenerative Disease IVD Revenue Share by Type (2021-2032) Figure 48. China Neurodegenerative Disease IVD Revenue Share by Application (2021-2032) Figure 49. Asia Neurodegenerative Disease IVD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Neurodegenerative Disease IVD Revenue Share by Type (2021-2032) Figure 51. Asia Neurodegenerative Disease IVD Revenue Share by Application (2021-2032) Figure 52. Asia Neurodegenerative Disease IVD Revenue Share by Region (2021-2032) Figure 53. Japan Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Neurodegenerative Disease IVD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Neurodegenerative Disease IVD Revenue Share by Type (2021-2032) Figure 61. SAMEA Neurodegenerative Disease IVD Revenue Share by Application (2021-2032) Figure 62. SAMEA Neurodegenerative Disease IVD Revenue Share by Country (2021-2032) Figure 63. Brazil Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Neurodegenerative Disease IVD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Biomarker Detection
  • Nucleic Acid Biomarker Detection
  • Others
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • ADx Neurosciences
  • Analytik Jena
  • Beckman Coulter
  • Creative Biolabs
  • Fujirebio
  • Genemedi
  • Medix Biochemica
  • Revvity
  • Roche Diagnostics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurodegenerative Disease IVD Market by Type
  3. 1.2.1 Global Neurodegenerative Disease IVD Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Protein Biomarker Detection
  5. 1.2.3 Nucleic Acid Biomarker Detection
  6. 1.2.4 Others
  7. 1.3 Neurodegenerative Disease IVD Market by Application
  8. 1.3.1 Global Neurodegenerative Disease IVD Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Alzheimer's Disease
  10. 1.3.3 Parkinson's Disease
  11. 1.3.4 Huntington's Disease
  12. 1.3.5 Amyotrophic Lateral Sclerosis (ALS)
  13. 1.3.6 Multiple System Atrophy (MSA)
  14. 1.3.7 Progressive Supranuclear Palsy (PSP)
  15. 1.3.8 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Neurodegenerative Disease IVD Market Dynamics
  1. 2.1 Neurodegenerative Disease IVD Industry Trends
  2. 2.2 Neurodegenerative Disease IVD Industry Drivers
  3. 2.3 Neurodegenerative Disease IVD Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease IVD Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neurodegenerative Disease IVD Market Perspective (2021-2032)
  2. 3.2 Global Neurodegenerative Disease IVD Growth Trends by Region
  3. 3.2.1 Global Neurodegenerative Disease IVD Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neurodegenerative Disease IVD Market Size by Region (2021-2026)
  5. 3.2.3 Global Neurodegenerative Disease IVD Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neurodegenerative Disease IVD Revenue by Players
  2. 4.1.1 Global Neurodegenerative Disease IVD Revenue by Players (2021-2026)
  3. 4.1.2 Global Neurodegenerative Disease IVD Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neurodegenerative Disease IVD Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neurodegenerative Disease IVD Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neurodegenerative Disease IVD Key Players Headquarters & Area Served
  7. 4.4 Global Neurodegenerative Disease IVD Players, Product Type & Application
  8. 4.5 Global Neurodegenerative Disease IVD Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neurodegenerative Disease IVD Market CR5 and HHI
  11. 4.6.3 2025 Neurodegenerative Disease IVD Tier 1, Tier 2, and Tier 3
5 Neurodegenerative Disease IVD Market Size by Type
  1. 5.1 Global Neurodegenerative Disease IVD Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurodegenerative Disease IVD Revenue by Type (2021-2032)
  3. 5.3 Global Neurodegenerative Disease IVD Revenue Market Share by Type (2021-2032)
6 Neurodegenerative Disease IVD Market Size by Application
  1. 6.1 Global Neurodegenerative Disease IVD Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neurodegenerative Disease IVD Revenue by Application (2021-2032)
  3. 6.3 Global Neurodegenerative Disease IVD Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 ADx Neurosciences
  2. 7.1.1 ADx Neurosciences Company Information
  3. 7.1.2 ADx Neurosciences Business Overview
  4. 7.1.3 ADx Neurosciences Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  5. 7.1.4 ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio
  6. 7.1.5 ADx Neurosciences Recent Developments
  7. 7.2 Analytik Jena
  8. 7.2.1 Analytik Jena Company Information
  9. 7.2.2 Analytik Jena Business Overview
  10. 7.2.3 Analytik Jena Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Analytik Jena Neurodegenerative Disease IVD Product Portfolio
  12. 7.2.5 Analytik Jena Recent Developments
  13. 7.3 Beckman Coulter
  14. 7.3.1 Beckman Coulter Company Information
  15. 7.3.2 Beckman Coulter Business Overview
  16. 7.3.3 Beckman Coulter Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Beckman Coulter Neurodegenerative Disease IVD Product Portfolio
  18. 7.3.5 Beckman Coulter Recent Developments
  19. 7.4 Creative Biolabs
  20. 7.4.1 Creative Biolabs Company Information
  21. 7.4.2 Creative Biolabs Business Overview
  22. 7.4.3 Creative Biolabs Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Creative Biolabs Neurodegenerative Disease IVD Product Portfolio
  24. 7.4.5 Creative Biolabs Recent Developments
  25. 7.5 Fujirebio
  26. 7.5.1 Fujirebio Company Information
  27. 7.5.2 Fujirebio Business Overview
  28. 7.5.3 Fujirebio Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Fujirebio Neurodegenerative Disease IVD Product Portfolio
  30. 7.5.5 Fujirebio Recent Developments
  31. 7.6 Genemedi
  32. 7.6.1 Genemedi Company Information
  33. 7.6.2 Genemedi Business Overview
  34. 7.6.3 Genemedi Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Genemedi Neurodegenerative Disease IVD Product Portfolio
  36. 7.6.5 Genemedi Recent Developments
  37. 7.7 Medix Biochemica
  38. 7.7.1 Medix Biochemica Company Information
  39. 7.7.2 Medix Biochemica Business Overview
  40. 7.7.3 Medix Biochemica Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Medix Biochemica Neurodegenerative Disease IVD Product Portfolio
  42. 7.7.5 Medix Biochemica Recent Developments
  43. 7.8 Revvity
  44. 7.8.1 Revvity Company Information
  45. 7.8.2 Revvity Business Overview
  46. 7.8.3 Revvity Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Revvity Neurodegenerative Disease IVD Product Portfolio
  48. 7.8.5 Revvity Recent Developments
  49. 7.9 Roche Diagnostics
  50. 7.9.1 Roche Diagnostics Company Information
  51. 7.9.2 Roche Diagnostics Business Overview
  52. 7.9.3 Roche Diagnostics Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio
  54. 7.9.5 Roche Diagnostics Recent Developments
8 North America
  1. 8.1 North America Neurodegenerative Disease IVD Revenue (2021-2032)
  2. 8.2 North America Neurodegenerative Disease IVD Revenue by Type (2021-2032)
  3. 8.2.1 North America Neurodegenerative Disease IVD Revenue by Type (2021-2026)
  4. 8.2.2 North America Neurodegenerative Disease IVD Revenue by Type (2027-2032)
  5. 8.3 North America Neurodegenerative Disease IVD Revenue Share by Type (2021-2032)
  6. 8.4 North America Neurodegenerative Disease IVD Revenue by Application (2021-2032)
  7. 8.4.1 North America Neurodegenerative Disease IVD Revenue by Application (2021-2026)
  8. 8.4.2 North America Neurodegenerative Disease IVD Revenue by Application (2027-2032)
  9. 8.5 North America Neurodegenerative Disease IVD Revenue Share by Application (2021-2032)
  10. 8.6 North America Neurodegenerative Disease IVD Revenue by Country
  11. 8.6.1 North America Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neurodegenerative Disease IVD Revenue by Country (2021-2026)
  13. 8.6.3 North America Neurodegenerative Disease IVD Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Neurodegenerative Disease IVD Revenue (2021-2032)
  2. 9.2 Europe Neurodegenerative Disease IVD Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neurodegenerative Disease IVD Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neurodegenerative Disease IVD Revenue by Type (2027-2032)
  5. 9.3 Europe Neurodegenerative Disease IVD Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neurodegenerative Disease IVD Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neurodegenerative Disease IVD Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neurodegenerative Disease IVD Revenue by Application (2027-2032)
  9. 9.5 Europe Neurodegenerative Disease IVD Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neurodegenerative Disease IVD Revenue by Country
  11. 9.6.1 Europe Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neurodegenerative Disease IVD Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neurodegenerative Disease IVD Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Neurodegenerative Disease IVD Revenue (2021-2032)
  2. 10.2 China Neurodegenerative Disease IVD Revenue by Type (2021-2032)
  3. 10.2.1 China Neurodegenerative Disease IVD Revenue by Type (2021-2026)
  4. 10.2.2 China Neurodegenerative Disease IVD Revenue by Type (2027-2032)
  5. 10.3 China Neurodegenerative Disease IVD Revenue Share by Type (2021-2032)
  6. 10.4 China Neurodegenerative Disease IVD Revenue by Application (2021-2032)
  7. 10.4.1 China Neurodegenerative Disease IVD Revenue by Application (2021-2026)
  8. 10.4.2 China Neurodegenerative Disease IVD Revenue by Application (2027-2032)
  9. 10.5 China Neurodegenerative Disease IVD Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neurodegenerative Disease IVD Revenue (2021-2032)
  2. 11.2 Asia Neurodegenerative Disease IVD Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neurodegenerative Disease IVD Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neurodegenerative Disease IVD Revenue by Type (2027-2032)
  5. 11.3 Asia Neurodegenerative Disease IVD Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neurodegenerative Disease IVD Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neurodegenerative Disease IVD Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neurodegenerative Disease IVD Revenue by Application (2027-2032)
  9. 11.5 Asia Neurodegenerative Disease IVD Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neurodegenerative Disease IVD Revenue by Country
  11. 11.6.1 Asia Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neurodegenerative Disease IVD Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neurodegenerative Disease IVD Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neurodegenerative Disease IVD Revenue (2021-2032)
  2. 12.2 SAMEA Neurodegenerative Disease IVD Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neurodegenerative Disease IVD Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neurodegenerative Disease IVD Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neurodegenerative Disease IVD Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neurodegenerative Disease IVD Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neurodegenerative Disease IVD Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neurodegenerative Disease IVD Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neurodegenerative Disease IVD Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neurodegenerative Disease IVD Revenue by Country
  11. 12.6.1 SAMEA Neurodegenerative Disease IVD Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neurodegenerative Disease IVD Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neurodegenerative Disease IVD Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst